Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Haeryoung Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4205-9081; OpenAlex author ID A5032641605. Sources: OpenAlex.

Their work

Papers
20 (first author 5, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
70
Papers, trials and grants by year

2012: 2 papers · 2013: 2 papers · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 3 papers · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 3 papers · 2022: 3 papers · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 20

  1. Prediction of tumor regression grade and identification of prognostic factors using CT and biological features in patients with pancreatic cancer who underwent… Co-author DOI 10.1177/02841851261424497↗
  2. Microscopic tumor mapping of post-neoadjuvant therapy pancreatic cancer specimens to predict post-surgical recurrence: A prospective cohort study. Co-author DOI 10.1016/j.pan.2024.03.013↗
  3. Parallel Analysis of Pre- and Postoperative Circulating Tumor DNA and Matched Tumor Tissues in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Cohor… Co-author DOI 10.1093/clinchem/hvac153↗
  4. Four-Tier Pathologic Tumor Regression Grading System Predicts the Clinical Outcome in Patients Who Undergo Surgical Resection for Locally Advanced Pancreatic C… Co-author DOI 10.5009/gnl20312↗
  5. Establishment of Patient-Derived Pancreatic Cancer Organoids from Endoscopic Ultrasound-Guided Fine-Needle Aspiration Biopsies. First author DOI 10.5009/gnl210166↗
  6. Preoperative assessment of the resectability of pancreatic ductal adenocarcinoma on CT according to the NCCN Guidelines focusing on SMA/SMV branch invasion. Co-author DOI 10.1007/s00330-021-07847-4↗
  7. Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A bi… Co-author DOI 10.1016/j.pan.2021.02.022↗
  8. Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX. Co-author DOI 10.5009/gnl20070↗
  9. Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ejso.2020.07.029↗
  10. Higher Tumor Cellularity in Resected Pancreatic Ductal Adenocarcinoma Is a Negative Prognostic Indicator. First author DOI 10.5009/gnl19180↗
  11. It is necessary to exam bottom and top slide smears of EUS-FNA for pancreatic cancer. First author DOI 10.1016/j.hbpd.2018.08.002↗
  12. Prognostic value of p21-activated kinase 4 in resected pancreatic cancer. Co-author DOI 10.1111/apm.12705↗
  13. The prognostic significance of cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Last author DOI 10.1177/1010428317718403↗
  14. IL2RG, identified as overexpressed by RNA-seq profiling of pancreatic intraepithelial neoplasia, mediates pancreatic cancer growth. Co-author DOI 10.18632/oncotarget.19848↗
  15. Presence of pancreatic intraepithelial neoplasia-3 in a background of chronic pancreatitis in pancreatic cancer patients. First author DOI 10.1111/cas.12744↗
  16. Having pancreatic cancer with tumoral loss of ATM and normal TP53 protein expression is associated with a poorer prognosis. Co-author DOI 10.1158/1078-0432.ccr-13-1239↗
  17. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Co-author DOI 10.1158/1078-0432.ccr-12-3092↗
  18. Serum miR-1290 as a marker of pancreatic cancer--response. Co-author DOI 10.1158/1078-0432.ccr-13-1899↗
  19. Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients. First author DOI 10.1111/j.1440-1827.2011.02772.x↗
  20. Postoperative prognostic predictors of pancreatic ductal adenocarcinoma: clinical analysis and immunoprofile on tissue microarrays. Co-author DOI 10.1245/s10434-012-2277-7↗

Closest collaborators

The 25 strongest of 70 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin‐Hyeok Hwang · 9 shared papers, 2012–2022 · strength 0.77
  2. Ho‐Seong Han · 8 shared papers, 2012–2024 · strength 0.76
  3. Yoo‐Seok Yoon · 7 shared papers, 2012–2024 · strength 0.73
  4. Jaihwan Kim · 6 shared papers, 2015–2022 · strength 0.64
  5. Jong-Chan Lee · 4 shared papers, 2018–2022 · strength 0.52
  6. Sae‐Jin Park · 2 shared papers, 2021–2026 · strength 0.52
  7. Hongbeom Kim · 4 shared papers, 2020–2022 · strength 0.48
  8. Jin‐Young Jang · 4 shared papers, 2020–2022 · strength 0.48
  9. Wooil Kwon · 4 shared papers, 2020–2022 · strength 0.48
  10. Jeongin Yoo · 1 shared paper, 2026 · strength 0.39
  11. Jung Hoon Kim · 1 shared paper, 2026 · strength 0.39
  12. Sang Hyub Lee · 3 shared papers, 2012–2022 · strength 0.28
  13. Soomin Ahn · 2 shared papers, 2020–2022 · strength 0.28
  14. Ji Kon Ryu · 3 shared papers, 2012–2022 · strength 0.28
  15. Woo Hyun Paik · 2 shared papers, 2021–2022 · strength 0.25
  16. Do‐Youn Oh · 2 shared papers, 2020–2021 · strength 0.22
  17. Eui Kyu Chie · 2 shared papers, 2020–2021 · strength 0.22
  18. Yeshong Park · 1 shared paper, 2024 · strength 0.20
  19. Yeon Bi Han · 1 shared paper, 2024 · strength 0.20
  20. MeeYoung Kang · 1 shared paper, 2024 · strength 0.20
  21. Jinju Kim · 1 shared paper, 2024 · strength 0.20
  22. Boram Lee · 1 shared paper, 2024 · strength 0.20
  23. Michael Goggins · 4 shared papers, 2013–2017 · strength 0.19
  24. Ralph H. Hruban · 4 shared papers, 2013–2017 · strength 0.19
  25. Hyunjin Park · 2 shared papers, 2017–2020 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.